MBD outlines cancer-drug testing expansion ahead of planned Kosdaq IPO
MBD CEO Gu Bo-seong outlined plans in Seoul to expand personalized cancer-drug testing and overseas sales of automated cell-culture equipment ahead of a planned Kosdaq listing. The company plans to use IPO proceeds for cancer-drug testing research, facility expansion and overseas growth. It aims to raise 19.2–23.4 billion won by offering 2 million new shares, with retail subscriptions scheduled for November 12–13.